Results 11 to 20 of about 4,502 (202)

In Vitro Biological Evaluation of Aprepitant Based ¹⁷⁷Lu-Radioconjugates

Pharmaceutics, 2022
Currently, the search for promising NK1R-positive tumor-targeting radiopharmaceuticals based on the structure of small molecular antagonists of neurokinin-1 receptor can be observed.
Paweł K. Halik, Przemysław Koźmiński, Joanna Matalińska, Piotr F. J. Lipiński, Aleksandra Misicka, Ewa Gniazdowska   +5 more
doaj   +2 more sources

Utility of Aprepitant in the Management of Pediatric Patients with Cyclical Vomiting Syndrome

Medicines
Introduction: Cyclical vomiting syndrome (CVS) is a recurrent debilitating illness characterized by intense episodes of nausea and emesis with widely varied pharmacological management across the country.
Aravind Thavamani, Sindhoosha Malay, Jasmine Khatana, Sujithra Velayuthan, Senthilkumar Sankararaman   +4 more
doaj   +2 more sources

Enhanced anti-angiogenic effects of aprepitant-loaded nanoparticles in human umbilical vein endothelial cells

Scientific Reports
Recent advancements in cancer therapy have led to the development of novel nanoparticle-based drug delivery systems aimed at enhancing the efficacy of chemotherapeutic agents.
Elif Kaya-Tilki, Ahmet Alper Öztürk, Selin Engür-Öztürk, Miriş Dikmen   +3 more
doaj   +2 more sources

Anti-Cancer Effect of Aprepitant on Nb4 Leukemic Cells

Majallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2017
BACKGROUND AND OBJECTIVE: Genetic studies have demonstrated that the neurokini-1 Receptor (NK1R (is frequently involved in the pathogenesis of wide assortment of human malignancies, including acute promyelocytic leukemia (APL).
E Razani, S Bayati, A Safaroghli Azar, D Bashash, AH Ghafari   +4 more
doaj   +1 more source

Aprepitant for Cough in Lung Cancer A Randomized Placebo-controlled Trial and Mechanistic Insights [PDF]

, 2020
Rationale: Effective cough treatments are a significant unmet need in patients with lung cancer. Aprepitant is a licensed treatment for nausea and vomiting, which blocks substance P activation of NK-1 (neurokinin 1) receptors, a mechanism also implicated
Yorke, J., Smith, Jaclyn A; id_orcid, Russell, P., Holt, Kimberley; id_orcid, Holt, Kimberley, Holt, K., Smith, J.A., Robinson, Ryan, Dockry, Rachel, Russell, Philip, Belvisi, Maria G, Yorke, Janelle, Blackhall, F., Dockry, Rachel; id_orcid, Smith, Jaclyn A, Birrell, Mark A, Robinson, R., Birrell, Mark A., Molasiotis, A., Blackhall, Fiona, Dockry, R., Belvisi, Maria G., Birrell, M.A., Molassiotis, Alex, Harle, A., Blackhall, Fiona; id_orcid, Belvisi, M.G., Harle, Amélie   +27 more
core   +1 more source

Prediction of Moderate to Severe Delayed Chemotherapy-Induced Nausea Using a Novel Algorithm Incorporating Individual Patient Factors. [PDF]

Cancer Med
ABSTRACT Purpose Chemotherapy‐induced vomiting and nausea (CINV) is difficult to accurately predict, especially in the delayed phase and can negatively affect a patient's' quality of life as well as reduce their motivation to continue lifesaving therapy.
Maity AP, Kjelstrom SD, Fleck KJ, Zeger EL, Ali ZA, Ghaneie A, Shevade AL, Gilman PB, Savior DC, Wallon UM.   +9 more
europepmc   +2 more sources

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Aprepitant Inhibits JNK and p38/MAPK to Attenuate Inflammation and Suppresses Inflammatory Pain

Frontiers in Pharmacology, 2022
Substance P contributes to the pathogenesis of pain by acting on NK-1R, specialized sensory neurons that detect noxious stimuli. Aprepitant, an antagonist of NK-1R, is widely used to treat chemotherapy-induced nausea and vomiting.
Yang Yang, Wei Zhou, Xiuqi Xu, Xianxiu Ge, Fei Wang, Guang-Qin Zhang, Lin Miao, Xueting Deng   +7 more
doaj   +1 more source

The Effect of SP/NK1R on the Expression and Activity of Catalase and Superoxide Dismutase in Glioblastoma Cancer Cells

Biochemistry Research International, 2021
Introduction. Glioblastoma is the most malignant brain tumor with different therapeutic protocols, including surgery, radiotherapy, and chemotherapy. Substance P (SP), a peptide released by sensory nerves, increases cellular excitability by activating ...
Faranak Korfi, Hossein Javid, Reza Assaran Darban, Seyed Isaac Hashemy   +3 more
doaj   +1 more source

Effect of combinations of dexamethasone-ondansetron and dexamethasone-ondansetron-aprepitant versus aprepitant alone for early postoperative nausea and vomiting after day care gynaecological laparoscopy: A randomised clinical trial

Indian Journal of Anaesthesia, 2021
Background and Aims: This study was designed to compare the effectiveness of the combination of dexamethasone–ondansetron with oral aprepitant alone and triple combination therapy with all three agents (dexamethasone-ondansetron and oral aprepitant) in ...
Ingilala L Thanuja, Satyen Parida, Sandeep K Mishra, Ashok S Badhe   +3 more
doaj   +1 more source